Changes of the echocardiographic data of ADPKD patients and control group during 6 years between the initial examination and the follow-up examination
| Parameter | ADPKD group (n=37) | Control group (n=40) | p-valuea |
|---|---|---|---|
| LVEDd (cm) | −0.08±0.45 | +0.06±0.32 | 0.036 |
| LVPWd (cm) | +0.03±0.18 | −0.01±0.16 | 0.49 |
| IVSd (cm) | +0.02±0.20 | +0.02±0.18 | 0.84 |
| AO (cm) | +0.08±0.33 | +0.28±0.32*** | 0.0044 |
| LA (cm) | +0.12±0.40 | +0.23±0.38*** | 0.35 |
| LVEF(%) | +0.42±4.20 | +1.00±4.56 | 0.44 |
| LVM (g) | +2.9±34.5 | +4.0±33.2 | 0.26 |
| LVMI-S (g/m2) | +0.5±18.6 | +1.4±17.5 | 0.24 |
| LVMI-H (g/m2.7) | +0.7±7.7 | +0.8±8.0 | 0.28 |
Anthropometric, clinical, and biochemical data of the ADPKD and control groups after 6-year follow-up
| Parameters | ADPKD group n=37 | Control group n=40 | p-value * |
|---|---|---|---|
| Age (years) | 44.63±10.96 | 43.97±9.4 | 0.84 |
| BMI (kg/m2) | 27.12±5.27 | 25.94±4.42 | 0.44 |
| WHR | 0.89±0.11 | 0.85±0.090 | 0.040 |
| BSA (m2) | 1.93±0.22 | 1.90±0.24 | 0.57 |
| SBP (mmHg) | 130.43±19.62 | 115.85±14.42 | 0.006 |
| DBP (mmHg) | 89.51±14.28 | 77.00±10.22 | 0.001 |
| e-GFRCKD EPI [mL/min/1.73 m2] | 80.55±26.4 | 114.41±26.50 | 0.038 |
| Hypertension [n, (%)] | 30 (81.1%) | 7 (17.50%) | <0.001 |
| ACE inhibitors [n, (%)] | 26 (70.3%) | 5 (12.50%) | <0.001 |
| LVH-S ESH/ESC 2007 (%) ** | 16.2 (%) | 2.5 (%) | 0.051 |
| LVH-S ESH/ESC 2013 (%) *** | 35.1 (%) | 10 (%) | 0.012 |
| LVH-H ESH/ESC 2017 (%)**** | 27.0 (%) | 7.5 (%) | 0.032 |
Comparison of the M-mode echocardiographic data of ADPKD patients and control group depending on the gender after six-year follow-upp
| Indexes | ADPKD women | Control women | p-value1 | ADPKD men | Control men | p-value2 |
|---|---|---|---|---|---|---|
| LVEDd (cm) | 4.75 (0.40) | 4.60 (0.30) | 0.20 | 5.30 (0.4) | 5.10 (0.7) | 0.98 |
| LVPWd (cm) | 1.00 (0.20) | 0.90 (0.20) | 0.002 | 1.10 (0.4) | 1.00 (0.2) | 0.13 |
| IVSd (cm) | 1.00 (0.30) | 0.80 (0.30) | 0.018 | 1.1 (0.3) | 1.00 (0.2) | 0.048 |
| AO (cm) | 2.85 (0.50) | 2.60 (0.40) | 0.013 | 3.20 (0.5) | 3.20 (0.2) | 0.50 |
| LA (cm) | 3.50 (0.60) | 3.10 (0.60) | 0.015 | 3.80 (0.7) | 3.70 (0.4) | 0.98 |
| LVEF (%) | 65.0 (5.0) | 70.0 (5.0) | 0.2 | 65.0 (5.0) | 65.0 (5.0) | 0.38 |
| LVM (g) | 148.1 (62.2) | 122.3 (34.7) | 0.0016 | 226.4 (89.6) | 199.3 (63.8) | 0.13 |
| LVMI-S g/m2 | 83.3 (29.4) | 71.4 (17.4) | 0.0065 | 104.6 (35.8) | 93.5 (38.2) | 0.13 |
| LVMI-H g/m2.7 | 38.3 (12.8) | 30.3 (11.4) | 0.018 | 48.0 (28.2) | 35.2 (14.9) | 0.084 |
Significant correlations of the echocardiographic data from follow-up examination with anthropometric, clinical and biochemical parameters from initial examination in ADPKD patients
| Parameters at the initial examination | ADPKD patients | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LVEDd | LA | LVPWd | IVSd | LVMI-S | LVMI-H | |||||||
| F | M | F | M | F | M | F | M | F | M | F | M | |
| BMI | +0.8^ | +0.62 | +0.68 | |||||||||
| WHR | +0.91^ | +0.59 | +0.53 | +0.66 | ||||||||
| SBP | +0.67* | +0.58* | +0.44 | +0.64 | +0.44 | +0.59 | ||||||
| DBP | +0.67* | +0.50 | +0.50 | +0.63 | +0.57 | |||||||
| Fasting glucose | ||||||||||||
| Fasting insulin | +0.53* | |||||||||||
| Fasting C-peptide | +0.67^ | +0.56 | ||||||||||
| HOMA%S | −0.48 | −0.56 | −0.61 | |||||||||
| Cholesterol-HDL | −0.50 | −0.46 | ||||||||||
| TG | +0.42 | +0.67* | −0.56* | |||||||||
| UA | +0.42 | +0.56 | −0.47 | +0.41 | ||||||||
| e-GFRCKD EPI | −0.52 | −0.77* | −0.65 | |||||||||
| Age | +0.7 | +0.019 | ||||||||||
Correlations of the delta echocardiographic data (the difference between the follow-up and the initial measurements) with anthropometric, clinical and biochemical parameters from the initial examination in the ADPKD patients
| Parameters at the initial examination | Delta echocardiographic data in the ADPKD patients | |
|---|---|---|
| LVPWd | IVSd | |
| BMI | +0.03 | −0.44^ |
| WHR | +0.10 | −0.33+ |
| SBP | +0.44* | −0.06 |
| DBP | +0.36+ | +0.08 |
| HbA1c | −0.15 | −0.34+ |
| TG | +0.02 | −0.43* |
| e-GFRCKD EPI | −0.30 | +0.14 |